Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2019
Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinibJun Zhao, Gen Lin, Minglei Zhuo, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2023
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III TrialHuiping Li, Yan Huang, Zhendong Chen, et al.Journal of Bone Oncology|February 25, 2025
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumorsMingchuan Zhao, Xichun Hu, Pengpeng Zhuang, et al.Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 TrialAnwen Xiong, Shengxiang Ren, Huaimin Liu, et al.The Lancet Regional Health. Western Pacific|March 7, 2023
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 studyYuankai Shi, Xintian Qin, Xingchen Peng, et al.Eclinicalmedicine|November 29, 2021
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind studyRui Wan, Xiaorong Dong, Qun Chen, et al.Pageof 4